NIA/AA for Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (NIA/AA IMPACT-AD Course)

NIH RePORTER · NIH · R25 · $426,043 · view on reporter.nih.gov ↗

Abstract

Project Summary There is an urgent need for improved therapies for Alzheimer’s Disease and Related Dementias (ADRD). Critical to the mission to develop treatments for and curb the public health impact of ADRD will be a new generation of ADRD scientists, especially scientists with the unique training and skills necessary to design and perform clinical trials. This training is rarely provided through the traditional course of medical or biostatistical education. Moreover, to develop improved therapies for ADRD, multidisciplinary expertise in clinical trials will be necessary, including medical specialists but also expertise in biostatistics, biomarkers, trial design, participant recruitment, study organization, and trial ethics. This proposal requests support for a first-of-its-kind training program in the essential elements of design and conduct of ADRD trials that will leverage the full infrastructure and expertise of the Alzheimer’s Clinical Trials Consortium (ACTC) and be conducted annually to enable a diverse range of clinicians, scientists and researchers to receive modern and robust training on ADRD clinical trials.

Key facts

NIH application ID
10410305
Project number
1R25AG076392-01
Recipient
UNIVERSITY OF SOUTHERN CALIFORNIA
Principal Investigator
Joshua Grill
Activity code
R25
Funding institute
NIH
Fiscal year
2022
Award amount
$426,043
Award type
1
Project period
2022-06-01 → 2027-03-31